Printer Friendly

Stem Cell Completes Secured Convertible Note Offering.

SCOTCH PLAINS, N.J. -- Stem Cell Innovations, Inc. (OTCBB: SCLL) announced today that it had raised $1 million through the issuance to an existing investor of a secured convertible note and warrants to purchase 10,000,000 shares of the Company's common stock. The convertible note, due November 16, 2007, is in the principal amount of $1 million, bears interest at the rate of 10% per annum, is secured by all the assets of the Company and its subsidiaries, and is convertible into 10,000,000 shares of the Company's common stock. The warrants are exercisable until November 16, 2011 at a price of $.12 per share. The note and the warrants are subject to full ratchet antidilution provisions. The investor has committed to invest an additional $1 million on the same terms, within 60 days

of the closing date, subject to the continued satisfaction by the Company of the conditions required to be satisfied with respect to the current offering. The Company paid a fee equal to $25,000 and 250,000 shares of common stock in connection with the transaction and will pay the same fee upon the completion of the additional $1 million investment.

About Stem Cell Innovations

Stem Cell Innovations is a cell biology company with facilities in Scotch Plains, NJ, Houston, TX and Leiden, the Netherlands. Our proprietary, human pluripotent stem cells, known as PluriCells[TM], have the potential to aid in drug discovery, toxicology, and cell therapy. We are in the process of making our patented pluripotent cell lines, which are eligible for federal funding in the United States, widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.

We are positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell technology greatly expands our currently marketed C3A human liver cell-based toxicology offerings.

Additional information is available at

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the differences could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 17, 2006
Previous Article:Hilton Raises the Flag at Woburn's Largest Hotel.
Next Article:Wipro and Manhattan Associates Partner for Providing Supply Chain Solutions to Retail Enterprises.

Related Articles
Cellular conversion turns brain into blood.
Medical Cannibalism.
Adult stem cells form blood vessels. (Retina Rescue).
Stem cell politics. (Insider Report).
Fertile soil for rational debate.
Perfect match: embryonic stem cells carry patients' DNA.
Stem cell roadblock.
Cell of Cells: The Global Race to Capture and Control the Stem Cell.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters